Metabolon (Durham, NC) a commercial-stage provider of biomarker discovery and analysis, closed a $13.1M Series D financing. Participants include Keating Capital, Sevin Rosen Funds, Aurora Funds, Harris & Harris Group, Syngenta Ventures and Fletcher Spaght.

Kythera Biopharmaceuticals (Calabasas, CA) a clinical-stage biopharmaceutical company focused on aesthetic dermatology, closed a $37.4M Series D financing. Participants include Versant Ventures, Arch Venture Partners, Prospect Venture Partners, Jafco Ventures, Invus Financial Advisors, BBT Capital Management, Altitude Life Science Ventures and Foley Ventures.

Tokai Pharmaceuticals (Cambridge, MA) a clinical-stage pharmaceutical company focused on prostate cancer, closed a $23M Series D financing. Participants include Novartis Venture Fund and Apple Tree Partners.

Teladoc (Dallas, TX) a commercial-stage on-demand telehealth services provider, closed a $18.6M Series D financing. Participants include Kleiner Perkins, Cardinal Partners, HLM Venture Partners, Trident Capital and New Capital Partners.

AM-Pharma (The Netherlands) a clinical-stage pharmaceutical company focused on acute kidney injury and ulcerative colitis, closed a $39.8M Series D financing. Participants include Ysios Capital Partners, Kurma Life Science Partners, Abbott Ventures, Shire Ventures, BB Biotech Ventures, Idinvest Partners, Forbion Capital Partners and Inventages Venture Capital.

Ambit Biosciences (San Diego, CA) a clinical-stage biopharmaceutical company focused on kinase inhibitors for the treatment of cancer and other conditions, closed a $30M Series D financing. Participants include Apposite Capital, Perseus-Soros Biopharmaceutical Fund, OrbiMed, Forward Ventures, Roche Venture Fund, MedImmune Ventures, Gimv, GrowthWorks, GeneChem, Radius Ventures and NovaQuest Capital Management.
The 2Q11 OnBioVC Trend Analysis [...]

OrSense (Israel) a commercial-stage medical device company focused on non-invasive measurements of oxygen saturation, hemoglobin, glucose and other blood parameters, closed $18M Series D financing. Participants include Israel HealthCare Ventures, Star Ventures and Lewis Trust Private Equity.

U-Systems (Sunnyvale, CA) a clinica-stage medical device company focused on automated breast ultrasound technology, closed a $6.5M Series D financing. Participants include iD SoftCapital Group, Lumira Capital, Radius Ventures and Sycamore Ventures.

Nexstim (Finland) a commercial-stage developer of non-invasive brain imaging technologies focused on cortical mapping prior to surgery, closed a $2.8M Series D financing, bringing the total round to $19.2M. Participants include Capricorn Health-tech Fund, Tekes, HealthCap, Sitra, Finnish Industry Investment, Lundbeckfond Ventures and Ilmarinen.

PixelOptics (Roanoke, VA) a commercial-stage developer of dynamic electronic focusing eyeglasses, closed a $35M Series D financing. Participants include Safeguard Scientifics, Delphi Ventures, Carlyle Group, Longitude Capital and Stark Investments.

Oxford Nanopore Technologies (United Kingdom) a development-stage medical device company focused on DNA sequencing via an electronic, label-free analysis of single molecule platform, closed a $28M Series D financing. Participants include Lansdowne Partners, IP Group, Invesco Perpetual and Redmile Group.

Tracon Pharmaceuticals (San Diego, CA) a clinical-stage biopharmaceutical company focused on cancer, closed a $14M Series D financing. Participants include Jafco Ventures, Nextech Invest, Arcus Ventures, Brookline Investments and BHP.

Circassia (United Kingdom) a clinical-stage specialty biopharmaceutical company focused on allergy and autoimmune conditions, closed a $98M Series D financing. Participants include Imperial Innovations and Invesco Perpetual.